Philip A. Hipskind

Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs

Michal Vieth, Miles G. Siegel, Richard E. Higgs et al. · Journal of Medicinal Chemistry · 2003 · 355 citations

Molecular Pharmacology, Drug Candidate Discovery, New Drug Candidates +15

Upregulation of Voluntary Alcohol Intake, Behavioral Sensitivity to Stress, and Amygdala Crhr1 Expression Following a History of Dependence

Wolfgang H. Sommer, Roberto Rimondini, Anita C. Hansson et al. · Biological Psychiatry · 2007 · 315 citations · Full text

Substance Abuse, Behavioral Sciences, Substance Use +15

3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-<i>b</i>]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism

Donald R. Gehlert, Andrea Cippitelli, Annika Thorsell et al. · Journal of Neuroscience · 2007 · 242 citations · Full text

Psychopharmacology, Pharmacotherapy, Experimental Pharmacology +20

Advent of Imidazo[1,2-<i>a</i>]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity

Garrett C. Moraski, Lowell D. Markley, Philip A. Hipskind et al. · ACS Medicinal Chemistry Letters · 2011 · 179 citations

Synthesis and Evaluation of a Series of Novel 2-[(4-Chlorophenoxy)methyl]- benzimidazoles as Selective Neuropeptide Y Y1 Receptor Antagonists

Hamideh Zarrinmayeh, Anne M. Nunes, Paul L. Ornstein et al. · Journal of Medicinal Chemistry · 1998 · 152 citations · Full text